(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) presented positive data from its Phase 3 study of its investigational medicine, JZP-258, for the treatment of cataplexy and excessive daytime sleepiness in ...

The companies had originally planned a higher dosage of JZP-386 in the phase I study which is a first-in-human study evaluating the safety, pharmacokinetics and pharmacodynamics of the candidate. The ...

Jazz Pharmaceuticals plc JAZZ announced that it has submitted a new drug application (“NDA”), seeking approval for JZP-258 as a treatment for cataplexy and excessive daytime sleepiness (“EDS”) ...

The FDA has accepted for filing with priority review Jazz Pharmaceuticals’ new drug application for JZP-258. The investigational medicine targets cataplexy and excessive daytime sleepiness associated ...

Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC). This is an ASCO Meeting Abstract ...

A novel, low-sodium drug is safe and effective for treating symptoms of narcolepsy in adults, new research suggests. Results of a phase 3 trial show participants who received the investigational drug ...

PALO ALTO, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that the U.S. Food and Drug Administration (FDA) has ...

DUBLIN & LEXINGTON, Mass.--(BUSINESS WIRE)--Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of the first Phase 1 clinical trial ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the first patients have been enrolled in a Phase 3 clinical development program evaluating the safety and efficacy of its investigational ...

Jazz Pharmaceuticals Public Limited CompanyJAZZ presented new data from a Human Abuse Liability (HAL) study on its investigational wake-promoting agent, JZP-110, at the annual meeting of the ...

DUBLIN, Sept. 25, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that positive data from the Phase 3 study of its investigational medicine, JZP-258, for the treatment of ...

PALO ALTO, Calif., Oct. 11 Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that the U.S. Food and Drug Administration (FDA) has sent the company a complete response letter (CRL) regarding ...